Hematologic Malignancy
Classic Hodgkin Lymphoma
CI-CAN-00002375CHLExplore in graph →
Hematologic41 active trials3 approved drugs
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002375CHLExplore in graph →
Clinical trials
114 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (14)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01896999 | Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04288726 | Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas | active not recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Aug 26, 2026 |
| NCT03150329 | Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. | active not recruiting | Phase 1 | 52 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05362773 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | active not recruiting | Phase 1 | 130 | MacroGenicsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03697408 | Itacitinib + Everolimus in Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 23 | University of PennsylvaniaOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05162976 | CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed | active not recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT05352828 | Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy(ACTION) | active not recruiting | Phase 1 | 15 | Tessa TherapeuticsINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
Data updated 20 hours agoSource updated Sep 29, 2026source: clinicaltrials